Stockreport

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vaxcyte, Inc.  (PCVX) 
PDF Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BL [Read more]